Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome
Therapeutic Apheresis and Dialysis · 2024
DOI: 10.1111/1744-9987.14094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2024. Verfasst von Kenichi Ito und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Plasmapheresis, Blood Viscosity, Immunoglobulin M. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Hyperviscosity syndrome (HVS) is a significant complication in Waldenström's macroglobulinemia (WM), although the significance of plasmapheresis in clinical practice has not been clarified. To confirm the efficacy and safety of plasmapheresis followed by primary therapy for WM with HVS, we retrospectively conducted this study.
Methods
Untreated WM with HVS, or serum immunoglobulin M (IgM) levels ≥4000 mg/dL, were analyzed. The basic therapeutic flow was conducted as follows: (1) performing plasmapheresis, (2) followed by primary therapy without rituximab, and (3) performing the second cycle. The serum IgM reduction rate and adverse events (AEs) were evaluated.
Results
Ten patients were enrolled. The median serum IgM levels at diagnosis, post‐plasmapheresis, after the first cycle of primary therapy, and after the second cycle were 5174, 2900, 3286, and 2657 mg/dL, respectively. No patients experienced IgM flare or bleeding AEs.
Conclusion
The therapeutic flow offers sufficient efficacy and safety in WM with HVS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
- Nephrology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
- Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
- Clinical Research Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
ORCID-Profile: Kenichi Ito, Naohiro Sekiguchi
Zitieren
APA
Ito, K., Kawasaki, T., Hirano, K., & Sekiguchi, N. (2024). Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14094
Vancouver
Ito K, Kawasaki T, Hirano K, Sekiguchi N. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome. Therapeutic Apheresis and Dialysis. 2024. doi:10.1111/1744-9987.14094
BibTeX
@article{Ito2024,
author = {Ito, Kenichi and Kawasaki, Tomoki and Hirano, Kazuhiko and Sekiguchi, Naohiro},
title = {Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome},
journal = {Therapeutic Apheresis and Dialysis},
year = {2024},
doi = {10.1111/1744-9987.14094}
}
EUVIMED